Verseon to Present Data on a New Class of Anticoagulants
FREMONT, Calif. – Verseon Corporation’s (AIM: VSN) David Kita, co-founder and Vice President of Research and Development, will present preclinical data on Verseon’s new class of anticoagulants at the 8th annual Biotech Showcase on January 12th, 2016 in San Francisco. Dr. Kita’s presentation will include recently obtained data from preclinical studies that demonstrate continuing and steady progress in Verseon’s anticoagulation program.
Dr. Kita commented on Verseon’s latest preclinical data. “The results we have obtained for our program represents compelling evidence that our drug candidates have lower bleeding risk than conventional therapies with equivalent or better therapeutic potential. This data will form an important part of our upcoming IND (Investigational New Drug) filings in the anticoagulant space.”
Verseon’s new class of oral, highly-selective, direct thrombin inhibitors show excellent results in preclinical efficacy studies and have pharmacokinetic profiles suitable for oral dosing. Furthermore, Verseon has demonstrated reduced risk of major bleeding for their drug candidates relative to current novel oral anticoagulants (NOACs).
Verseon is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.
For further information please contact
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
|Abchurch Communications Ltd (PR Advisers)||+44 (0) 20 7398 7719|
|Jamie Hooper / Alex Shaw|